Browse drugs

…CD16+/CD137+) at 1 week after the first infusion, regardless of W0180 dose (online supplemental figure S7).Of the pro-inflammatory cy…

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…city, with G3/4 events reported in 22% compared with 14% in the nivolumab monotherapy arm. An update presented at the European Society of…

…izumab had higher AE incidence without additional efficacy over pembrolizumab alone. Safety results were overall consistent with the known sa…

…state health sector in which several novel cancer drugs such as osimertinib, alectinib and immunotherapy are not approved for use in advanc…

…umab) are often used in ovarian and cervical cancers. ICIs (eg, pembrolizumab) are effective in mismatch repair-deficient endometrial cancer …

… from €18 to €14,567. By cancer type, the patients treated with pembrolizumab 2 mg/kg included: 16 with head and neck cancer, nine with cervi…

… reduction in NK and B cells. When 177Lu-PSMA was combined with pembrolizumab, we saw dynamic changes in non-Treg T cell subsets (CD4+ and CD…

…rolled in a first-line phase II trial of the anti-PD-1 antibody nivolumab.13 Together, these data suggest then an immunologically enriche…

…ced or metastatic disease, with 75% presenting brain metastases.Pembrolizumab discontinuation was due to disease progression (39%), immune-re…

…tional Health Service in England (NICE) have recommended dosing pembrolizumab by weight.3 4 Aim and Objectives To assess the economic impact …

…Background In Study 309/KEYNOTE-775 ( NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progre…